Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients' experience within a population-based study.

Tai-Jan Chiu,Yung-Yeh Su,Shih-Hung Yang,Chung-Pin Li,Li Yuan Bai,Nai Jung Chiang,Shih-Chang Chuang,Yan-Shen Shan,De-Chuan Chan,Li-Tzong Chen,Chia-Jui Yen,Cheng Ming Peng,Yen-Yang Chen,Jen-Shi Chen,Wen-Chi Chou

Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients' experience within a population-based study.

2021

Tai-Jan Chiu
Yung-Yeh Su
Shih-Hung Yang
Chung-Pin Li
Li Yuan Bai
Nai Jung Chiang
Shih-Chang Chuang
Yan-Shen Shan
De-Chuan Chan
Li-Tzong Chen
Chia-Jui Yen
Cheng Ming Peng
Yen-Yang Chen
Jen-Shi Chen
Wen-Chi Chou

Background:Liposomal irinotecan (nal-IRI) plus 5-fluorouracil and leucovorin (5-FU/LV) is currently the standard second-line treatment for patients with pancreatic ductal adenocarcinoma (PDAC) afte...

Keywords:

Oncology
pancreatic ductal adenocarcinoma
population based study
Toxicity
dose reduction
Liposomal Irinotecan
Pancreatic cancer
Internal medicine
Medicine
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations